N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome
Status:
Withdrawn
Trial end date:
2021-01-30
Target enrollment:
Participant gender:
Summary
We would study whether there is any measurable benefit of the administration of nebulized
n-acetyl-cysteine to acute respiratory distress syndrome patients starting within 48 hours of
intubation and mechanical ventilation.